Drug Profile
Zavegepant - Pfizer
Alternative Names: BHV 3500; BMS-742413; BMS-742413-03; Vazegepant; Vazegepant - Pfizer; Zavegepant hydrochloride; ZAVZPRETLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Pfizer
- Class Anti-infectives; Antiallergics; Antimigraines; Indazoles; Piperazines; Piperidines; Quinolines; Small molecules
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II/III COVID-19 respiratory infection
- Phase I Allergic asthma
Most Recent Events
- 12 Dec 2023 Pfizer completes a phase I pharmacokinetics trial in Healthy adult volunteers in China (Intranasal) (NCT05960032)
- 29 Nov 2023 Phase-III clinical trials in Migraine (Treatment-experienced) in China (Intranasal) (NCT05989048)
- 27 Oct 2023 Pfizer plans a phase III trial for Migraine in November 2023 (Intranasal)(NCT06103734)